Experimental data in cell cultures and animal models suggest that sulodexide and glycosaminoglycans are potentially effective drugs to treat chronic kidney diseases and prevent progression to renal failure. However, no conclusive evidence support the use of them in human renal disease. In acute and chronic glomerulonephritis, only few studies have been performed. Sulodexide has been more intensely investigated in diabetic nephropathy (DN) where the body of data supports its effectiveness as an antialbuminuric agent in early stages. Unfortunately, there is no study in DN patients on the effect of sulodexide on clinical end points.

Sulodexide and glycosaminoglycans in the progression of renal disease.

MASOLA, Valentina;Zaza, Gianluigi;Gambaro G.
2014

Abstract

Experimental data in cell cultures and animal models suggest that sulodexide and glycosaminoglycans are potentially effective drugs to treat chronic kidney diseases and prevent progression to renal failure. However, no conclusive evidence support the use of them in human renal disease. In acute and chronic glomerulonephritis, only few studies have been performed. Sulodexide has been more intensely investigated in diabetic nephropathy (DN) where the body of data supports its effectiveness as an antialbuminuric agent in early stages. Unfortunately, there is no study in DN patients on the effect of sulodexide on clinical end points.
FGF-2; diabetic nephropathy; glycosaminoglycans; heparanase-1
File in questo prodotto:
File Dimensione Formato  
NDT 2014.pdf

solo utenti autorizzati

Tipologia: Versione dell'editore
Licenza: Accesso ristretto
Dimensione 93.37 kB
Formato Adobe PDF
93.37 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/669361
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact